| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_498ad1aab67bf72d85b8d836934f3777
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3891c33f69124714595b835e4fd652e7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1787
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01J20-3251
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K17-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-723 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B01J20-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2013-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a70429fdffbe8372ceb3762144f957bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23762caaf60433f599b69ed44536530c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f9e022c23b4bc3de744d491723d3380
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40deb9c4fa1dd92870cdcd4c0e146e3d |
| publicationDate |
2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9574017-B2 |
| titleOfInvention |
Peptides having binding affinity to an antibody which recognizes an epitope on an α1 loop 2 or β2 loop 1 of an adrenoreceptor |
| abstract |
A peptide having an ED 50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular α1 loop 2 or β2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of γ-secretase activity, an increased release of β-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED 50 value is measured by bioassay. |
| priorityDate |
2008-01-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |